

## IACH 2021 Program

Friday, September 24, 2021	
12:45-13:00	Welcome: Mohamad Mohty, France & Arnon Nagler, Israel
13:00-14:50	Opening Session: State of the art therapy in ...
13:00-13:20	CLL: <i>TBA</i>
13:20-13:40	CML: <i>TBA</i>
13:40-14:00	Hodgkin lymphoma: Ali Bazarbachi, Lebanon
14:00-14:20	Mantle cell lymphoma: <i>TBA</i>
14:20-14:50	Panel Discussion
14:50-15:00	Break
15:00-16:50	Session 1: Immunotherapy
15:00-15:20	Immune modulation prior and post HSCT for AML: Gesine Bug, Germany
15:20-15:40	TCR Engineering: <i>TBA</i>
15:40-16:00	Anti-virus CTLs: <i>TBA</i>
16:00-16:20	Gamma/delta T cells: Jurgen Kuball, Netherlands
16:20-16:50	Panel Discussion
16:50-17:00	Break
17:00-18:50	Session 2: Transplant indications in ...
17:00-17:20	AML: Arnon Nagler, Israel
17:20-17:40	ALL: <i>TBA</i>
17:40-18:00	MPN: <i>TBA</i>
18:00-18:20	MDS: Corey Cutler, USA
18:20-18:50	Panel Discussion
18:50-19:00	Break
19:00-19:30	Plenary lecture: Hagop Kantarjian, USA

Saturday, September 25, 2021	
09:00-11:20	Session 3: Advances in transplant complications
09:00-09:20	Acute GVHD: Iskra Pusic, USA
09:20-09:40	Chronic GVHD: Zinaida Perić, Croatia
09:40-10:00	CMV infection at the era of letermovir: Bipin Savani, USA
10:00-10:20	Endothelium-related complications: Selim Corbacioglu, Germany
10:20-10:40	EBV-PTLD: Rafael de la Cámara, Spain
10:40-11:20	Panel Discussion
11:20-11:30	Break
11:30-13:20	Session 4: Advances in AML therapy
11:30-11:50	The case for Vyxeos: <i>TBA</i>
11:50-12:10	The case for oral azacytidine: Amer Zeidan, USA
12:10-12:30	The case for venetoclax: <i>TBA</i>
12:30-12:50	The case for Flt3 inhibitors: <i>TBA</i>
12:50-13:20	Panel Discussion
13:20-13:30	Break
13:30-15:00	Industry Symposium
15:00-15:30	MTE Session
15:00-15:30	Break
15:30-17:20	Session 5: Advances in rare entities

15:30-15:50	BPDCN: <b>Naveen Pemmaraju</b> , USA
15:50-16:10	Mastocytosis: <i>TBA</i>
16:10-16:30	Aplastic anemia: <i>TBA</i>
16:30-16:50	Waldenstrom disease: <i>TBA</i>
16:50-17:20	Panel Discussion
17:20-17:30	<i>Break</i>
<b>17:30-19:30</b>	<b>Session 6: Bispecific antibodies and antibody-drug conjugates in ...</b>
17:30-17:50	Lymphoma: <i>TBA</i>
17:50-18:10	Myeloma: <b>Salomon Manier</b> , France
18:10-18:30	AML: <i>TBA</i>
18:30-18:50	ALL: <b>Eolia Brissot</b> , France
18:50-19:30	Panel Discussion

<b>Sunday, September 26, 2021</b>	
<b>09:00-10:50</b>	<b>Session 7: State of the art in HSCT</b>
09:00-09:20	Optimizing stem cell collection: <i>TBA</i>
09:20-09:40	PTCy for GVHD prophylaxis: <b>Didier Blaise</b> , France
09:40-10:00	Optimal choice of donor: <b>Annalisa Ruggeri</b> , Italy
10:00-10:20	Bloodless HSCT: <b>Bhagirathbhai Dholaria</b> , USA
10:20-10:50	Panel Discussion
10:50-11:00	<i>Break</i>
<b>11:00-12:50</b>	<b>Session 8: CAR T cells in ...</b>
11:00-11:20	ALL: <b>Jordan Gauthier</b> , USA
11:20-11:40	CLL: <b>Mohamed Kharfan-Dabaja</b> , USA
11:40-12:00	Myeloma: <b>Mohamad Mohty</b> , France
12:00-12:20	Lymphoma: <b>Anna Sureda</b> , Spain
12:20-12:50	Panel Discussion
12:50-13:00	<i>Break</i>
<b>13:00-13:15</b>	<b>Closing Remarks: Mohamad Mohty</b> , France & <b>Arnon Nagler</b> , Israel